Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000341198

Medchemexpress LLC Fgti-2734 (mesylate) | 2702297-24-1 | 99.7% | 10 MM 1 ML
SDP

Catalog No. 5000341198
Encompass_Preferred

FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor. It can prevent membrane localization of KRAS, which helps to solve KRAS resistance and thwart mutant KRAS patient-derived pancreatic tumors.

  • Functions as a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor.
  • Exhibits IC50s of 250 nM for FT and 520 nM for GGT.
  • Prevents membrane localization of KRAS.
  • Addresses KRAS resistance.
  • Thwarts mutant KRAS patient-derived pancreatic tumors.
  • Induces apoptosis in mutant KRAS-dependent human cancer cells (in vitro).
  • Inhibits protein prenylation of HDJ2, RAP1A, KRAS, and NRAS (in vitro).
  • Inhibits tumor growth in mutant KRAS-dependent tumors (in vivo).

Catalog No. 50-003-41198 Supplier Medchemexpress LLC Supplier No. HY128350A10MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor. It can prevent membrane localization of KRAS, which helps to solve KRAS resistance and thwart mutant KRAS patient-derived pancreatic tumors.

  • Functions as a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor.
  • Exhibits IC50s of 250 nM for FT and 520 nM for GGT.
  • Prevents membrane localization of KRAS.
  • Addresses KRAS resistance.
  • Thwarts mutant KRAS patient-derived pancreatic tumors.
  • Induces apoptosis in mutant KRAS-dependent human cancer cells (in vitro).
  • Inhibits protein prenylation of HDJ2, RAP1A, KRAS, and NRAS (in vitro).
  • Inhibits tumor growth in mutant KRAS-dependent tumors (in vivo).

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.